Trebananib: Additional Phase III data

Additional data from the double-blind, international Phase III TRINOVA-1 trial in over 900 women with recurrent partially platinum-sensitive or platinum-resistant ovarian cancer, primary peritoneal cancer or fallopian

Read the full 276 word article

User Sign In